Why Acadia Healthcare Is Back On Investors’ Radar
Acadia Healthcare Company (ACHC) is drawing fresh attention after recent figures showed slower admissions growth alongside declines in earnings per share and free cash flow margin, raising questions about the resilience of its business model.
See our latest analysis for Acadia Healthcare Company.
The share price has moved sharply in the short term, with a 30 day share price return of 38.9% and a 90 day gain of 62.4%. However, the 1 year total shareholder return of 20.8% and 3 year total shareholder return of 66.5% highlight that longer term investors are still sitting on substantial losses. This suggests that recent momentum reflects a reassessment of future risks and cash generation rather than a clean bill of health.
If Acadia's recent swing has you rethinking your watchlist, this could be a good moment to scan for other healthcare names using the 36 healthcare AI stocks
With admissions growth slowing, earnings per share under pressure and free cash flow weaker, yet the stock still trading at a sizeable intrinsic discount, you have to ask: is this a reset buying opportunity, or is the market already pricing in better days ahead?
Most Popular Narrative: 99.7% Overvalued
Acadia Healthcare's narrative fair value of $11.94 sits well below the last close at $23.85, framing a wide gap that the most followed thesis tries to explain.
ACHC’s valuation often reflects investor concern around margins and regulatory scrutiny. But it may understate the company’s long-term positioning within a structurally growing healthcare segment.
This is not a high-growth technology story. It is a capacity-and-execution story in a market where demand is persistent and under-supplied. If Acadia continues to expand responsibly while maintaining care quality, its relevance is likely to increase rather than fade.
Want to see what sits behind that sharp discount to the narrative fair value? The core assumptions focus on revenue expansion, margin repair, and a future earnings profile built on consistent, capacity led growth. Curious how those moving parts combine to justify that pricing gap.
Result: Fair Value of $11.94 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the narrative can still be shaken if operational execution slips, or if regulatory and reimbursement pressures weigh further on margins and cash generation.
Find out about the key risks to this Acadia Healthcare Company narrative.
Another View: DCF Points the Other Way
The narrative fair value of $11.94 suggests Acadia Healthcare is heavily overvalued, yet our DCF model presents a very different perspective, with a future cash flow value of $118.12 implying the shares trade at a steep discount. When two methods disagree this much, which story do you trust?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
The split between narrative and DCF views makes Acadia feel anything but straightforward, so this is a moment to act quickly and test the numbers against your own expectations by weighing its 3 key rewards and 2 important warning signs
Looking For More Investment Ideas?
If Acadia has sharpened your focus, do not stop here. Broaden your watchlist now and let fresh ideas compete for a place in your portfolio.
- Spot potential mispricings early by scanning the market for companies trading below what their fundamentals suggest using the 61 high quality undervalued stocks
- Target income opportunities by focusing on companies with higher yields and resilient payouts through the 12 dividend fortresses
- Prioritise resilience by filtering for businesses with healthy balance sheets and solid fundamentals using the solid balance sheet and fundamentals stocks screener (39 results)
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com